Structured evidence table for Resistant Starch Gut Health Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Resistant Starch Gut Health Randomized Trial | Purpose of review Resistant starch (RS) has been widely investigated as a dietary component with potential metabolic benefits, including improved insulin sensitivity, lipid profile, and inflammatory markers. | 4 | Tavares IRG (2026) | Resistant Starch as a Functional Nutrient to Control Cardiometabolic Risk Factors in Humans: An Integrative Review. |
| Resistant Starch Gut Health Randomized Trial | This integrative review aimed to synthesize evidence on the effects of RS consumption in dietary interventions on metabolic and cardiovascular parameters in adults and older adults. | 4 | Tavares IRG (2026) | Resistant Starch as a Functional Nutrient to Control Cardiometabolic Risk Factors in Humans: An Integrative Review. |
| Resistant Starch Gut Health Randomized Trial | Recent findings RS intake, particularly RS2 and RS3, was associated with significant reductions in postprandial glucose, insulin, and HOMA-IR, as well as improvements in total cholesterol, LDL-C, and triglycerides. | 4 | Tavares IRG (2026) | Resistant Starch as a Functional Nutrient to Control Cardiometabolic Risk Factors in Humans: An Integrative Review. |
| Resistant Starch Gut Health Randomized Trial | However, clinical findings remain inconsistent, particularly regarding RS type and dosage. | 4 | Tavares IRG (2026) | Resistant Starch as a Functional Nutrient to Control Cardiometabolic Risk Factors in Humans: An Integrative Review. |
Source documents